Showing results (221-230 of 319) with videos related to
Sort By:
Pageof 32
Journal of Virology|March 29, 2003
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatmentsThomas D Wu, Celia A Schiffer, Matthew J Gonzales, et al.Journal of Virology|April 22, 2016
HIV-1 Protease, Reverse Transcriptase, and Integrase VariationSoo-Yon Rhee, Kris Sankaran, Vici Varghese, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2002
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patientsNancy S Shulman, Michael D Hughes, Mark A Winters, et al.AIDS (London, England)|July 19, 2006
Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapyAsha R Kallianpur, Todd Hulgan, Jeffrey A Canter, et al.The Pharmacogenomics Journal|August 9, 2007
The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathyJ A Canter, D W Haas, A R Kallianpur, et al.Journal of Virology|August 22, 2008
Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutationsYumi Mitsuya, Vici Varghese, Chunlin Wang, et al.Viruses|November 27, 2024
Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving RilpivirinePavithra Nagarajan, Jinru Zhou, Giulia Di Teodoro, et al.Vaccines|January 8, 2025
Post-COVID-19 Vaccination and Long COVID: Insights from Patient-Reported DataTom C Quach, Mitchell G Miglis, Lu Tian, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|July 1, 2006
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384Rajesh T Gandhi, John Spritzler, Ellen Chan, et al.The Journal of Infectious Diseases|April 1, 1994
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutationsR W Shafer, M J Kozal, M A Winters, et al.Pageof 32